KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.98

Statin initiation and early stroke recurrence in the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke Trial (POINT) trial population.

Elham Azizi, Shyam Prabhakaran, James R Brorson

J Stroke Cerebrovasc Dis 34(7) 108349

PMID40381866
PMCIDPMC12180576
DOI10.1016/j.jstrokecerebrovasdis.2025.108349
发表日期2025-05-17
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

BACKGROUND: Benefits of statin therapy in reducing the long-term risk of ischemic stroke are well-established, but the immediate protective effect of statin therapy on risks of early stroke recurrence after an initial ischemic event are not established. METHODS: In this secondary analysis of POINT data, we evaluated the effects of statins on early stroke recurrence (within 7 days) and recurrence over 90 days. We also examined the effect of early statin initiation in the subgroup of subjects not on statins prior to the index event, using logistic and proportional hazards models. RESULTS: In the POINT trial, 175 of 267 (65.5 %) of ischemic stroke recurrences were early (within 7 days). Baseline statin treatment at the time of study entry was associated with decreased odds of early ischemic stroke recurrence in adjusted logistical regression analysis (OR 0.70, 95 % CI 0.50-0.99, P = 0.04), an effect only marginally significant in adjusted Cox proportional hazard analyses (HR 0.72, 95 % CI 0.52-1.01, P = 0.05). In the subset of subjects not taking statin medications at baseline, initiation of statin treatment had no significant protective effect against early stroke recurrence (adjusted HR 0.80, 95 % CI 0.54-1.20, P = 0.28). CONCLUSIONS: In the POINT trial population, prior treatment with statin was marginally associated with decreased odds of early recurrence of stroke. However initiating statin treatment had no detectable effect in reducing risk of early stroke recurrence. The POINT trial provides no evidence for an immediate protective effect of statin initiation against early stroke recurrence.

KM 提取结果

1 个 Figure · 1 个 KM 面板

进入结果中心
KM Figure1 个面板

Fig. 3.

Fig. 3. Adjusted Cox proportional hazard analysis of risk of stroke recurrence in the subgroup of subjects not on statin treatment at baseline, stratified by the initiation of statin by the time of the day 7 visit. Numbers of subjects at risk in groups not on statin at baseline and on statin at baseline are given for days 0 and 6. The effect of statin initiation was not significant (HR 0.80, 95 % CI 0.54–1.20, P = 0.28 in adjusted analysis with specified imputation of missing values, and HR 0.82, 95 % CI 0.57-1.18, P = 0.28 in adjusted analysis using multiple imputations of missing values).

Fig._3

risk of stroke recurrence

Fig. 3. · Panel Fig._3

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel Fig._3 是同一 Fig. 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线 1:off origin start
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1.Fig. 1. Flow diagram of numbers of study subjects included and excluded at each stage of analysis.
非 KM Figure
Fig. 2.Fig. 2. Adjusted Cox proportional hazard analyses of risk of stroke recurrence stratified by baseline statin use over the initial 7 days. Numbers of subjects at risk in groups not on statin at baseline and on statin at baseline are given for days 0 and 6. The effect of baseline statin use was only marginally significant (HR 0.72, 95 % CI 0.52–1.01, P = 0.05 in adjusted analysis with specified imputation of missing values, and HR 0.69, 95 % CI 0.52–0.99, P = 0.04 in adjusted analysis using multiple imputations of missing values).
非 KM Figure